Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ESMO Open. 2022 Aug;7(4):100548. doi: 10.1016/j.esmoop.2022.100548. Epub 2022 Jul 16.
Herpes zoster (HZ) is the infectious reactivation of the varicella-zoster virus. HZ is more frequent in immunocompromised subjects, including patients with cancer. HZ complications can even last for years with a consequent delay in treatment of the underlying malignancy and with an unfavorable impact on quality of life. Nowadays, HZ is a vaccine-preventable disease: the recent approval of adjuvanted glycoprotein E-based recombinant zoster vaccine has changed preventive perspectives in immunocompromised subjects. Recombinant zoster vaccine induced both strong humoral and cellular immune responses also in immunocompromised patients. The question is, therefore, to which categories of cancer patients we should recommend HZ vaccination. Based on a careful review of the available data present in the literature, including recommendations and expert opinions, we report the position of the Associazione Italiana di Oncologia Medica on HZ vaccination in adult patients with solid tumors, thus providing clinical practice advice in a field where clear-cut information is missing.
带状疱疹（HZ）是水痘带状疱疹病毒的感染性再激活。HZ 在免疫功能低下的人群中更为常见，包括癌症患者。HZ 并发症甚至可能持续数年，从而延迟对潜在恶性肿瘤的治疗，并对生活质量产生不利影响。如今，HZ 是一种可通过疫苗预防的疾病：最近批准的含佐剂糖蛋白 E 重组带状疱疹疫苗改变了免疫功能低下人群的预防观点。重组带状疱疹疫苗在免疫功能低下的患者中也能诱导强烈的体液和细胞免疫反应。因此，问题是我们应该向哪些癌症患者推荐 HZ 疫苗接种。基于对文献中现有数据的仔细审查，包括建议和专家意见，我们报告了意大利肿瘤医学协会关于成人实体瘤患者 HZ 疫苗接种的立场，从而在缺乏明确信息的领域提供了临床实践建议。
